Dr. Keith C. Bible on Treatments Beyond First-Line Lenvatinib in Thyroid Cancer
Bible says most oncologists would consider lenvatinib as a first-line therapy for patients who require systemic therapy where there are not suitable, focal palliative options.
The Challenges of Treating Follicular Cell-Derived Thyroid Carcinoma
Keith C. Bible, MD, PhD, professor of oncology, Mayo Clinic, discusses the challenges associated with treating patients with follicular cell-derived thyroid carcinoma.